# CRISPR Therapeutics Shares Rise as ARK ETFs Boost Stake Ahead of Clinical Data

- URL: https://stocks.freetheai.org/news/crispr-therapeutics-shares-rise-as-ark-etfs-boost-stake-ahead-of-clinical-data-c3b27d
- Published: 2026-10-12T11:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:CRSP](https://stocks.freetheai.org/symbols/NASDAQ-CRSP)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

CRISPR Therapeutics AG (CRSP) saw its stock rise 5.85% to $53.39 after ARK ETFs increased their stake in the biotechnology company. The business is now listed as a major position within the ARK Innovation ETF portfolio for October 2026.

The expanded stake reflects increased investment interest in the company's gene-editing technology. The firm continues to move forward with its clinical pipeline, focusing on in vivo lipid-editing treatments.

Looking ahead, market participants will watch for the presentation of Phase 1b clinical data for CTX310 (ANGPTL3). CRISPR Therapeutics AG plans to present these results at the AHA Scientific Sessions on November 9, 2026.

## Key points

- Shares of CRISPR Therapeutics AG (CRSP) rose 5.85% to $53.39.
- ARK ETFs expanded their position in the company, making it a major holding in the ARK Innovation ETF.
- The company is preparing to release Phase 1b trial data for CTX310 (ANGPTL3).
- The clinical data from the in vivo lipid-editing program will be presented at the AHA Scientific Sessions on November 9, 2026.

## Questions and answers

### Why did CRISPR Therapeutics stock rise today?

Shares of CRISPR Therapeutics AG rose 5.85% to $53.39 after ARK ETFs increased their holdings, listing the biotech company as a major position in the ARK Innovation ETF portfolio.

### When will CRISPR Therapeutics present CTX310 Phase 1b data?

The company is scheduled to present Phase 1b clinical trial results for CTX310 (ANGPTL3) at the AHA Scientific Sessions on November 9, 2026.

### What is CTX310?

CTX310 (ANGPTL3) is a clinical candidate in CRISPR Therapeutics AG's in vivo lipid-editing program.